- Home
- ARQT
as 05-29-2025 4:00pm EST
Arcutis Biotherapeutics Inc is a medical dermatology company. It is developing treatments for patients with immune-mediated dermatological diseases and conditions. It is leveraging recent advances in immunology and inflammation to develop differentiated therapies against biologically validated targets to solve persistent treatment challenges in serious diseases of the skin. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population.
| Founded: | 2016 | Country: | United States |
| Employees: | N/A | City: | WESTLAKE VILLAGE |
| Market Cap: | 1.7B | IPO Year: | 2020 |
| Target Price: | $18.80 | AVG Volume (30 days): | 2.1M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 6 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.04 | EPS Growth: | N/A |
| 52 Week Low/High: | $6.99 - $17.75 | Next Earning Date: | 05-06-2025 |
| Revenue: | $212,819,000 | Revenue Growth: | 100.03% |
| Revenue Growth (this year): | 61.15% | Revenue Growth (next year): | 37.98% |
Stock Insider Trading Activity of Arcutis Biotherapeutics Inc. (ARQT)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Heron Patrick J | ARQT | Director | May 21 '25 | Buy | $13.66 | 5,040 | $68,821.20 | 22,534 | |
| Edwards Larry Todd | ARQT | See Remarks | May 19 '25 | Sell | $14.07 | 7,451 | $104,849.73 | 183,104 | |
| Heron Patrick J | ARQT | Director | May 15 '25 | Buy | $13.62 | 2,520 | $34,316.86 | 22,534 | |
| Heron Patrick J | ARQT | Director | May 9 '25 | Buy | $13.60 | 6,300 | $85,691.34 | 22,534 | |
| Burnett Patrick | ARQT | See Remarks | May 8 '25 | Sell | $13.59 | 3,871 | $52,623.15 | 115,468 | |
| Matsuda Masaru | ARQT | See Remarks | May 2 '25 | Sell | $15.20 | 5,030 | $76,453.49 | 204,399 | |
| Watanabe Todd Franklin | ARQT | See Remarks | May 2 '25 | Sell | $15.19 | 11,448 | $173,916.87 | 913,795 | |
| Welgus Howard G. | ARQT | Director | May 1 '25 | Sell | $14.64 | 10,000 | $146,357.00 | 111,944 | |
| Topper David Joseph | ARQT | Chief Financial Officer | Apr 2 '25 | Sell | $15.80 | 9,600 | $151,698.24 | 182,774 | |
| Welgus Howard G. | ARQT | Director | Apr 1 '25 | Sell | $15.12 | 10,000 | $151,236.00 | 111,944 |
Latest Arcutis Biotherapeutics Inc. News
ARQT Breaking Stock News: Dive into ARQT Ticker-Specific Updates for Smart Investing
MT Newswires
7 days ago
Arcutis Biotherapeutics' Foam Psoriasis Treatment Gets FDA Approval
GlobeNewswire
7 days ago
Arcutis’ ZORYVE® (roflumilast) Topical Foam 0.3% Approved by U.S. FDA for the Treatment of Plaque Psoriasis in Adults and Adolescents Ages 12 and Older
GlobeNewswire
15 days ago
New Consensus Statements on Impact of Genital Psoriasis on Patients from Genital Psoriasis Wellness Consortium Published in Journal of the European Academy of Dermatology and Venereology Clinical Practice
TipRanks
21 days ago
Arcutis Biotherapeutics: Zoryve foam treatment resulted in major improvements
Simply Wall St.
22 days ago
Arcutis Biotherapeutics First Quarter 2025 Earnings: Beats Expectations
Thomson Reuters StreetEvents
22 days ago
Q1 2025 Arcutis Biotherapeutics Inc Earnings Call
GlobeNewswire
23 days ago
Arcutis Announces Publication of Positive Data from ARRECTOR Trial Evaluating ZORYVE® (roflumilast) Foam 0.3% in Individuals with Psoriasis in Journal of American Medical Association Dermatology
GuruFocus.com
23 days ago
Arcutis Biotherapeutics Inc (ARQT) Q1 2025 Earnings Call Highlights: Record Revenue Growth and ...
Compare ARQT vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ARQT Arcutis Biotherapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.